Sagimet Biosciences Stock Forum

$Sagimet Biosciences (SGMT.US)$ Sagimet Biosciences Presented Data From FASCINATE-2 Phase 2B Trial Of Denifanstat Versus Placebo In Biopsy-Confirmed Metabolic Dysfunction-Associated Steatohepatitis Patients At The European Association For The Study Of The Liver Congress Benzinga · 4 mins  Denifanstat achieved statistically significant results on primary and secondary liver biopsy endpoints in the ITT population, including both histology endpoints recommended in the FDA draft guidance for ac...

Here are the levels to watch on this low volume drop.
Larger Image: tradingview.com...
$Sagimet Biosciences (SGMT.US)$

$Sagimet Biosciences (SGMT.US)$ Sagimet Biosciences Inc - End-of-Phase 2 Meeting With U.S. Food and Drug Administration (FDA) Expected in Q2 of 2024

$Sagimet Biosciences (SGMT.US)$
NEWS
Sagimet Announces Oral Presentation of Data from the Phase 2b FASCINATE-2 Study of Denifanstat in MASH at EASL International Liver Congress 2024

$Sagimet Biosciences (SGMT.US)$ back to 20

$Sagimet Biosciences (SGMT.US)$ hurry up and short it already market makers, take your L  and move on. so the big boys can buy this out

$Pfizer (PFE.US)$  Phase 2
$Leap Therapeutics (LPTX.US)$  Phase 2
$Vera Therapeutics (VERA.US)$  Phase 2b
$4D Molecular Therapeutics (FDMT.US)$  Phase 2
$Adverum Biotechnologies (ADVM.US)$  Phase 2
$Denali Therapeutics (DNLI.US)$  Phase 2
$Akero Therapeutics (AKRO.US)$  Phase 2b
$Spruce Biosciences (SPRB.US)$  Phase 2
$Xencor (XNCR.US)$  Phase 2
$Alnylam Pharmaceuticals (ALNY.US)$  Phase 2
$Harmony Biosciences (HRMY.US)$  Phase 2
$Annexon (ANNX.US)$  Phase 2a
$Roivant Sciences (ROIV.US)$...

$Sagimet Biosciences (SGMT.US)$ Sagimet Biosciences Announces Proposed Public Offering of Series A Common Stock
SAN MATEO, Calif., Jan. 23, 2024 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. ("Sagimet") (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN) inhibitors designed to target dysfunctional metabolic and fibrotic pathways, today announced the commencement of an underwritten public offering of 9,000,000 shares of its Series A common st...